Roche Wins FDA Approval for Breakthrough Leukemia Drug

Swiss pharmaceutical giant Roche has received the green light from the U.S. Food and Drug Adminstration (FDA) to sell Gazyva (obinutuzumab), its new agent to treat chronic lymphocytic leukemia (CLL) in combination with the chemotherapeutic agent chlorambucil.

Peak sales of the potential blockbuster drug are estimated at at least $1 billion, annually, with some estimates higher. Approval by EU authorities is expected for Q3 2014.

Gazyva is the first treatment approved under the FDA's Breakthrough Therapy program, and approval was given earlier than most observers assumed. The agency had been expected to report in mid-December. Roche said that when combined with chemotherapy, the new drug demonstrated an 84% reduction in the risk of disease worsening or death, compared to chemotherapy alone.

The monoclonal antibody discovered by Roche Glycart, a wholly owned, independent research unit of Roche based near Zurich, Switzerland, is designed to attach to CD20, a protein found only on B-cells. It attacks targeted cells both directly and together with the body's immune system, and some reports said it has been shown to be more efficacious than its predecessor Rituxan (rituximab), whose patent is set to expire.

Gazyva will be jointly marketed in the US by Roche-owned Genentech and Biogen Idec. Roche scientists are also exploring the use of Gazyva in other cancers such as non-Hodgkins lymphoma.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.